Target Value Study to Evaluate the Safety and Efficacy of the Taurus NXT® Transcatheter Aortic Valve System for the Treatment of Severe Calcific Aortic Stenosis
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 150 participants.
Also called NCT07908225
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 150 participants
- Registry
-
NCT07908225
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07908225. Allocation not applicable; no masking; primary purpose treatment. Start 2021-09-10 (actual); primary completion 2024-02-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Target Value Study to Evaluate the Safety and Efficacy of the Taurus NXT® Transcatheter Aortic Valve System for the Treatment of Severe Calcific Aortic Stenosis
- Condition
- Aortic Stenosis
- Intervention (Device)
- TAVR (transcatheter aortic valve replacement)
- Lead sponsor
- Peijia Medical Technology (Suzhou) Co., Ltd.
Record details
- Record id
cardio:ct-nct07908225- Content hash
dd0648adbf955ae889738cb513fdd1a7436aa44f884830a115daf1fd422d0ab9